Epizyme, Inc.
EPZM
|
$1.47
-1.34%
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-1.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 247,496,185
http://www.epizyme.com
Sec Filling | Patents | 203 employees
(US) Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
cancer ovarian cancer t-cell lungs genetic leukemia ceiling
Drugs
TAZVERIK (tazemetostat)add to watch list Paper trade email alert is off
Press-releases
Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $54.5 1.77% 1.74% 600K
|
|
| O: 0.2%
H: 5.99%
C: 5.65%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
MTEM | $1.485 -6.01% -6.4% 37K
|
Health Technology
|
| O: -2.94%
H: 3.03%
C: 3.03%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -0.6%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.66%
H: 0.64%
C: -1.11%
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: 1.1%
H: 0.27%
C: -1.64%
companies growth market
ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer
Published: 2024-01-03 (Crawled : 13:30) - prnewswire.com
INFIQ | $0.0001 3000.0% 680
|
Manufacturing
|
| O: -13.79%
H: 100.0%
C: -14.0%
The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight
Published: 2023-11-22 (Crawled : 22:00) - prnewswire.com
BPTH | News 0 d | $4.26 31.48% 23.94% 83M
|
Health Technology
| Email alert
Add to watchlist
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
IGMS | $7.4 -8.98% -9.86% 450K
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
| Email alert
Add to watchlist
IOVA M | $11.72 -0.68% -0.68% 3.6M
|
Health Technology
| Email alert
Add to watchlist
NRIX 2 d | $14.43 2.49% 2.43% 970K
|
Health Technology
| Email alert
Add to watchlist
RVMD S | $35.81 -2.74% -2.82% 1M
|
Health Technology
| Email alert
Add to watchlist
TGTX | News | $14.0 1.3% 1.29% 3.5M
|
Health Technology
| Email alert
Add to watchlist
XNCR | $18.98 -0.47% -0.47% 470K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
cell market
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Published: 2023-09-12 (Crawled : 00:00) - globenewswire.com
HCM | $16.38 -0.43% -0.43% 190K
|
Health Technology
|
| O: -1.67%
H: 2.31%
C: 1.22%
study
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
Published: 2023-06-13 (Crawled : 11:00) - investor.alkermes.com
ENDPQ | $0.0006 -50.0% 620K
|
n/a
|
| O: -47.17%
H: 110.71%
C: 96.43%
IRM | $74.42 -0.97% -0.13% 870K
|
Finance
|
| O: -0.18%
H: 0.94%
C: 0.2%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.37%
H: 0.84%
C: 0.46%
AMRX | $5.36 -1.83% -1.87% 840K
|
Health Technology
|
| O: 0.4%
H: 8.7%
C: 1.98%
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -0.93%
VRTX | News | $393.51 0.1% 0.1% 950K
|
Health Technology
|
| O: 0.08%
H: 1.04%
C: 0.36%
UTHR | $237.16 0.79% 0.78% 480K
|
Health Technology
|
| O: -0.65%
H: 2.13%
C: 1.37%
RARE F | $43.38 -1.65% -1.68% 770K
|
Health Technology
|
| O: 0.72%
H: 2.22%
C: 0.5%
SRPT | $116.59 -1.1% -1.12% 500K
|
Health Technology
|
| O: 0.55%
H: 2.23%
C: -0.71%
SAGE | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: 0.07%
H: 2.89%
C: 1.85%
PTCT | $24.71 -1.79% -1.82% 820K
|
Health Technology
|
| O: -0.3%
H: 2.48%
C: 1.97%
PRTA 4 | $20.6 -1.91% -1.94% 570K
|
Health Technology
|
| O: 0.29%
H: 5.34%
C: 4.38%
NBIX M | $132.49 -0.56% -0.56% 550K
|
Health Technology
|
| O: 0.05%
H: 2.35%
C: 2.29%
MDXG | $6.17 -2.53% -2.59% 540K
|
Health Technology
|
| O: 0.85%
H: 1.34%
C: -0.17%
LPTX | $2.96 -1.33% -1.35% 100K
|
Health Technology
|
| O: 0.0%
H: 9.63%
C: 9.63%
JAZZ | $109.3 2.05% 2.01% 560K
|
Health Technology
|
| O: -0.02%
H: 1.93%
C: 1.16%
IRWD | $7.59 -0.78% -0.79% 3.6M
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -3.42%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.17%
H: 1.25%
C: 0.46%
INFI | $0.016 12.5% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.76%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.48%
H: 1.44%
C: 0.24%
IDXX | $477.785 -0.1% -0.1% 400K
|
Health Technology
|
| O: 0.31%
H: 1.9%
C: 1.42%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: 0.52%
CYCN | $3.2182 12.62% 180
|
Health Technology
|
| O: 6.44%
H: 0.41%
C: -1.94%
BPMC | News | $88.9 0.59% 0.58% 730K
|
Health Technology
|
| O: 0.62%
H: 2.47%
C: 0.53%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -1.06%
H: 6.94%
C: -2.15%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.07%
H: 2.64%
C: 2.23%
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.19%
H: 1.58%
C: 0.64%
ACAD | $17.08 -0.64% -0.64% 990K
|
Health Technology
|
| O: 0.12%
H: 1.83%
C: 1.58%
IBIO | $1.77 -6.35% -0.57% 180K
|
Health Technology
|
| O: 16.68%
H: 3.53%
C: -11.59%
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
Published: 2022-10-27 (Crawled : 08:00) - biospace.com/
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
sales growth
HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
Published: 2022-08-25 (Crawled : 12:00) - prnewswire.com
FULC | $7.06 -1.26% -1.27% 530K
|
Health Technology
|
| O: 0.87%
H: 2.47%
C: -5.18%
therapeutics
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Published: 2022-08-12 (Crawled : 22:00) - biospace.com/
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
| Email alert
Add to watchlist
acquisition
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
THRX | $4.06 0.49% 0
|
|
| O: -1.07%
H: 0.0%
C: -5.91%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -0.33%
H: 0.67%
C: -1.34%
results
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-09 (Crawled : 12:20) - biospace.com/
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -1.67%
H: 0.0%
C: 0.0%
update results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10